- United States
- /
- Healthcare Services
- /
- NYSE:DVA
DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may consider DaVita Inc. (NYSE:DVA) as an attractive investment with its 14.7x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's limited.
DaVita certainly has been doing a good job lately as its earnings growth has been positive while most other companies have been seeing their earnings go backwards. One possibility is that the P/E is low because investors think the company's earnings are going to fall away like everyone else's soon. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
Check out our latest analysis for DaVita
How Is DaVita's Growth Trending?
The only time you'd be truly comfortable seeing a P/E as low as DaVita's is when the company's growth is on track to lag the market.
Retrospectively, the last year delivered an exceptional 93% gain to the company's bottom line. As a result, it also grew EPS by 30% in total over the last three years. Therefore, it's fair to say the earnings growth recently has been respectable for the company.
Looking ahead now, EPS is anticipated to climb by 1.7% per year during the coming three years according to the seven analysts following the company. Meanwhile, the rest of the market is forecast to expand by 10% per annum, which is noticeably more attractive.
With this information, we can see why DaVita is trading at a P/E lower than the market. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
The Bottom Line On DaVita's P/E
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
We've established that DaVita maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. It's hard to see the share price rising strongly in the near future under these circumstances.
You should always think about risks. Case in point, we've spotted 3 warning signs for DaVita you should be aware of, and 1 of them doesn't sit too well with us.
Of course, you might also be able to find a better stock than DaVita. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:DVA
DaVita
Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Undervalued with proven track record.